116 related articles for article (PubMed ID: 25629129)
1. Re: a functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle.
Atala A
J Urol; 2014 Jul; 192(1):275-6. PubMed ID: 25629129
[No Abstract] [Full Text] [Related]
2. A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle.
Sadananda P; Drake MJ; Paton JF; Pickering AE
J Pharmacol Exp Ther; 2013 Nov; 347(2):506-15. PubMed ID: 24008334
[TBL] [Abstract][Full Text] [Related]
3. Re: Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Wein AJ
J Urol; 2015 Jun; 193(6):2148. PubMed ID: 25986844
[No Abstract] [Full Text] [Related]
4. Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor.
D' Agostino G; Maria Condino A; Calvi P
Eur J Pharmacol; 2015 Jul; 758():115-22. PubMed ID: 25861936
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Sasamata M
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):247-53. PubMed ID: 23239087
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Masuda N
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):1001-8. PubMed ID: 23832377
[TBL] [Abstract][Full Text] [Related]
8. Mirabegron.
Goulooze SC; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2015 Oct; 80(4):762-4. PubMed ID: 25819590
[TBL] [Abstract][Full Text] [Related]
9. Mirabegron (Myrbetriq) for overactive bladder.
Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
[No Abstract] [Full Text] [Related]
10. The β3-adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome.
Masunaga K; Chapple CR; McKay NG; Yoshida M; Sellers DJ
Neurourol Urodyn; 2010 Sep; 29(7):1320-5. PubMed ID: 20151470
[TBL] [Abstract][Full Text] [Related]
11. Mirabegron: potential off target effects and uses beyond the bladder.
Dehvari N; da Silva Junior ED; Bengtsson T; Hutchinson DS
Br J Pharmacol; 2018 Nov; 175(21):4072-4082. PubMed ID: 29243229
[TBL] [Abstract][Full Text] [Related]
12. β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase.
Cernecka H; Kersten K; Maarsingh H; Elzinga CR; de Jong IJ; Korstanje C; Michel MC; Schmidt M
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jul; 388(7):749-59. PubMed ID: 25956403
[TBL] [Abstract][Full Text] [Related]
13. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Wyndaele JJ
BJU Int; 2012 Jul; 110(2 Pt 2):E143. PubMed ID: 22734513
[No Abstract] [Full Text] [Related]
14. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
Svalø J; Nordling J; Bouchelouche K; Andersson KE; Korstanje C; Bouchelouche P
Eur J Pharmacol; 2013 Jan; 699(1-3):101-5. PubMed ID: 23246623
[TBL] [Abstract][Full Text] [Related]
15. Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder.
Rouget C; Rekik M; Camparo P; Botto H; Rischmann P; Lluel P; Palea S; Westfall TD
Pharmacol Res; 2014 Feb; 80():14-20. PubMed ID: 24378642
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice.
Calmasini FB; de Oliveira MG; Alexandre EC; da Silva FH; da Silva CPV; Candido TZ; Antunes E; Mónica FZ
Neurourol Urodyn; 2017 Aug; 36(6):1511-1518. PubMed ID: 27794199
[TBL] [Abstract][Full Text] [Related]
17. Effects of L-arginine, mirabegron, and oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, rhythmic bladder contractions in the rat.
Aizawa N; Homma Y; Igawa Y
Neurourol Urodyn; 2015 Apr; 34(4):368-74. PubMed ID: 24532414
[TBL] [Abstract][Full Text] [Related]
18. An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant.
Tasler S; Baumgartner R; Behr-Roussel D; Oger-Roussel S; Gorny D; Giuliano F; Ney P
Eur J Pharm Sci; 2012 Aug; 46(5):381-7. PubMed ID: 22430195
[TBL] [Abstract][Full Text] [Related]
19. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.
Aizawa N; Homma Y; Igawa Y
Eur Urol; 2012 Dec; 62(6):1165-73. PubMed ID: 22981677
[TBL] [Abstract][Full Text] [Related]
20. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
